EFFECT OF OMEPRAZOLE ON NOCTURNAL INTRAGASTRIC PH IN CIRRHOTICS WITH INADEQUATE ANTISECRETORY RESPONSE TO RANITIDINE

被引:17
作者
WALKER, S
KLOTZ, U
SAREMASLANI, A
TREIBER, G
BODE, JC
机构
[1] ROBERT BOSCH KRANKENHAUS,DEPT CLIN PHARMACOL,W-7000 STUTTGART,GERMANY
[2] ROBERT BOSCH KRANKENHAUS,DEPT CLIN CHEM,W-7000 STUTTGART,GERMANY
关键词
DRUG RESISTANCE; HISTAMINE H2-RECEPTOR BLOCKERS; H+K+-ADENOSINE TRIPHOSPHATASE INHIBITOR; INTRAGASTRIC PH MONITORING; LIVER CIRRHOSIS; OMEPRAZOLE; RANITIDINE;
D O I
10.1159/000200691
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Failure of acid suppression by H-2-receptor antagonists has been observed, and recently we have found a higher frequency of patients with inadequate antisecretory response among patients with cirrhosis of the liver. In the present study comprising 16 cirrhotics with inadequate antisecretory response to 300 mg of ranitidine, we tested the effect of 40 mg omeprazole. Nighttime intragastric pH was continuously monitored, and a rise in the intragastric pH above 4.0 for more than 6 h following the oral dose at 18.00 h was considered as response. The median pH profile during the omeprazole treatment was significantly higher than with ranitidine (p less-than-or-equal-to 0.001). In contrast to 300 mg ranitidine, which despite sufficient plasma levels 2 and 4 h after intake (762 +/- 431 and 802 +/- 668 ng/ml) resulted in a rise in the nighttime intragastric pH above 4 only for 1.8 +/- 1.7 h, after omeprazole for at least 5 days, the intragastric pH was for 10. 1 +/- 2.4 of 12 h above 4 during the night (p < 0.00 1). The omeprazole plasma levels were 611 +/- 323 and 881 +/- 533 ng/ml after 2 and 4 h. The data obtained with intragastric pH monitoring indicate that the H+K+-ATPase inhibitor omeprazole is able to overcome the H-2-blocker resistance in cirrhotics.
引用
收藏
页码:179 / 184
页数:6
相关论文
共 43 条
[1]   OMEPRAZOLE IN THE MANAGEMENT OF REFRACTORY DUODENAL-ULCER [J].
BARDHAN, KD .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :63-75
[2]  
BARDHAN KD, 1987, GASTROENTEROLOGY, V92, P1306
[3]  
BLUM AL, 1986, NEW ENGL J MED, V314, P715
[4]  
BOUTAGY J, 1984, J LIQ CHROMATOGR, V7, P1651, DOI 10.1080/01483918408074073
[5]   THERAPY WITH OMEPRAZOLE IN PATIENTS WITH PEPTIC ULCERATIONS RESISTANT TO EXTENDED HIGH-DOSE RANITIDINE TREATMENT [J].
BRUNNER, G ;
CREUTZFELDT, W ;
HARKE, U ;
LAMBERTS, R .
DIGESTION, 1988, 39 (02) :80-90
[6]   PHARMACOLOGY AND TOXICOLOGY OF OMEPRAZOLE WITH SPECIAL REFERENCE TO THE EFFECTS ON THE GASTRIC-MUCOSA [J].
CARLSSON, E ;
LARSSON, H ;
MATTSSON, H ;
RYBERG, B ;
SUNDELL, G .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1986, 21 :31-38
[7]   OMEPRAZOLE - PHARMACOKINETICS AND METABOLISM IN MAN [J].
CEDERBERG, C ;
ANDERSSON, T ;
SKANBERG, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :33-42
[8]   SHORT-DURATION TREATMENT OF DUODENAL-ULCER WITH OMEPRAZOLE AND RANITIDINE - RESULTS OF A MULTI-CENTRE TRIAL IN GERMANY [J].
CLASSEN, M ;
DAMMANN, HG ;
DOMSCHKE, W ;
HENGELS, KJ ;
HUTTEMANN, W ;
LONDONG, W ;
REHNER, M ;
SIMON, B ;
WITZEL, L ;
BERGER, J .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (06) :210-215
[9]  
CLASSEN M, 1985, DEUT MED WOCHENSCHR, V110, P626
[10]   OMEPRAZOLE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN PEPTIC-ULCER DISEASE AND ZOLLINGER-ELLISON SYNDROME [J].
CLISSOLD, SP ;
CAMPOLIRICHARDS, DM .
DRUGS, 1986, 32 (01) :15-47